{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T19:18:26Z","timestamp":1788895106260,"version":"build-2803163510"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273537"],"award-info":[{"award-number":["82273537"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) have demonstrated significant therapeutic benefits but are also associated with skin-related adverse reactions. The specific characteristics of severe adverse reactions caused by ICIs remain unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the disease characteristics of Stevens-Johnson syndrome (SJS)\/toxic epidermal necrolysis (TEN)-like reactions induced by ICIs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Cases of ICI-induced SJS\/TEN were collected from PubMed, CNKI, Wanfang Data Knowledge Service Platform, and Guangdong Provincial People\u2019s Hospital, with a search time span ranging from March 2011 to January 31, 2024.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 110 cases of SJS, TEN, and overlapping SJS\/TEN were analyzed, with a male predominance (62%). Mucous membrane involvement was observed in 71 patients (66%), though less frequently than in classic SJS\/TEN. The mean latency period was 64 days, varying by subtype (105 days for SJS and 53 days for TEN). Combination therapy with ICIs was associated with a higher mortality risk (P\u2005=\u2005.029). Deceased patients exhibited shorter latency periods (mean 30.3 days) and more severe mucosal involvement (up to 100%), although the differences were not statistically significant. Systemic glucocorticoid therapy was the cornerstone of treatment for SJS\/TEN-like reactions. The addition of immunoglobulin showed a trend toward improved outcomes but did not significantly affect mortality or cure rates compared to glucocorticoid monotherapy. The combination of systemic glucocorticoids and antibiotics demonstrated a promising trend, with a higher proportion of patients in the improvement\/cure group using this regimen (P\u2005=\u2005.085).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study summarizes the clinical characteristics of ICI-induced SJS\/TEN-like reactions, providing insights into their features and potential treatment strategies for severe skin-related adverse events induced by ICIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf143","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T05:15:51Z","timestamp":1749532551000},"source":"Crossref","is-referenced-by-count":7,"title":["Clinical characteristics of Stevens-Johnson syndrome\/toxic epidermal necrolysis-like reactions induced by immune checkpoint inhibitors"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2911-7074","authenticated-orcid":false,"given":"Ziliang","family":"Zheng","sequence":"first","affiliation":[{"name":"Guangdong Cardiovascular Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences , Guangzhou 510080 ,","place":["China"]},{"name":"Department of Dermatology, Guangdong Provincial People\u2019s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University , Guangzhou 510080 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2901-4273","authenticated-orcid":false,"given":"Zhu","family":"Shen","sequence":"additional","affiliation":[{"name":"Guangdong Cardiovascular Institute, Guangdong Provincial People\u2019s Hospital, Guangdong Academy of Medical Sciences , Guangzhou 510080 ,","place":["China"]},{"name":"Department of Dermatology, Guangdong Provincial People\u2019s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University , Guangzhou 510080 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"2025061001154903700_CIT0001","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1111\/ijd.14811","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int J Dermatol"},{"key":"2025061001154903700_CIT0002","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1097\/CM9.0000000000003250","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: updates in pathophysiology and management","volume":"137","author":"Hasegawa","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"2025061001154903700_CIT0003","doi-asserted-by":"publisher","first-page":"949520","DOI":"10.3389\/fmed.2022.949520","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review of PubMed\/MEDLINE case reports from 1980 to 2020","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med"},{"key":"2025061001154903700_CIT0004","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jaad.2024.06.066","article-title":"Retrospective cohort study characterizing PD-1\/PD-L1 checkpoint inhibition associated Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"91","author":"Chen","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"2025061001154903700_CIT0005","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00403-024-03061-6","article-title":"Immune checkpoint inhibitor associated epidermal necrosis, beyond SJS and TEN: a review of 98 cases","volume":"316","author":"Bray","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"2025061001154903700_CIT0006","doi-asserted-by":"publisher","first-page":"1414136","DOI":"10.3389\/fimmu.2024.1414136","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"key":"2025061001154903700_CIT0007","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3390\/medicina57090895","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of diagnosis and management","volume":"57","author":"Frantz","year":"2021","journal-title":"Medicina (Kaunas, Lithuania)"},{"key":"2025061001154903700_CIT0008","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.21037\/tcr-21-470","article-title":"Pembrolizumab-induced autoimmune Stevens-Johnson syndrome\/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report","volume":"10","author":"Cao","year":"2021","journal-title":"Translational Cancer Res"},{"key":"2025061001154903700_CIT0009","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.intimp.2005.11.012","article-title":"Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding","volume":"6","author":"French","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"2025061001154903700_CIT0010","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2147\/JIR.S454673","article-title":"Emerging Insights into Stevens-Johnson Syndrome and toxic epidermal necrolysis induced by immune checkpoint inhibitor and tumor-targeted therapy","volume":"17","author":"Lin","year":"23512024","journal-title":"J Inflammation Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf143\/63458970\/oyaf143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf143\/63458970\/oyaf143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T05:15:51Z","timestamp":1749532551000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf143\/8159169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf143","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]},"article-number":"oyaf143"}}